Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., Kantarjian, Hagop M.
Published in Blood (26.07.2018)
Published in Blood (26.07.2018)
Get full text
Journal Article
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe
Published in Leukemia (01.05.2021)
Published in Leukemia (01.05.2021)
Get full text
Journal Article
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Kreitman, Robert J, Dearden, Claire, Zinzani, Pier Luigi, Delgado, Julio, Robak, Tadeusz, le Coutre, Philipp D, Gjertsen, Bjørn T, Troussard, Xavier, Roboz, Gail J, Karlin, Lionel, Gladstone, Douglas E, Kuptsova-Clarkson, Nataliya, Liu, Shiyao, Patel, Priti, Rotolo, Federico, Mitry, Emmanuel, Pastan, Ira, Giles, Francis
Published in Journal of hematology and oncology (24.02.2021)
Published in Journal of hematology and oncology (24.02.2021)
Get full text
Journal Article
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, Timothy P, Hochhaus, Andreas, Kantarjian, Hagop M, Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D, Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D, Kemp, Charisse, Larson, Richard A, Saglio, Giuseppe
Published in Haematologica (Roma) (01.07.2014)
Published in Haematologica (Roma) (01.07.2014)
Get full text
Journal Article
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
Cortes, Jorge E, De Souza, Carmino Antonio, Ayala, Manuel, Lopez, Jose Luis, Bullorsky, Eduardo, Shah, Sandip, Huang, Xiaojun, Babu, K Govind, Abdulkadyrov, Kudrat, de Oliveira, José Salvador Rodrigues, Shen, Zhi-Xiang, Sacha, Tomasz, Bendit, Israel, Liang, Zhizhou, Owugah, Tina, Szczudlo, Tomasz, Khanna, Sadhvi, Fellague-Chebra, Rafik, le Coutre, Philipp D
Published in The Lancet. Haematology (01.12.2016)
Published in The Lancet. Haematology (01.12.2016)
Get more information
Journal Article
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, Hochhaus, Andreas
Published in Journal of cancer research and clinical oncology (01.05.2018)
Published in Journal of cancer research and clinical oncology (01.05.2018)
Get full text
Journal Article
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, Hagop M., Giles, Francis J., Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Radich, Jerald P., Saglio, Giuseppe, Hughes, Timothy P., Martinelli, Giovanni, Kim, Dong-Wook, Shou, Yaping, Gallagher, Neil J., Blakesley, Rick, Baccarani, Michele, Cortes, Jorge, le Coutre, Philipp D.
Published in Blood (27.01.2011)
Published in Blood (27.01.2011)
Get full text
Journal Article
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
Hochhaus, Andreas, Baccarani, Michele, Giles, Francis J., le Coutre, Philipp D., Müller, Martin C., Reiter, Andreas, Santanastasio, Helene, Leung, Mimi, Novick, Steven, Kantarjian, Hagop M.
Published in Journal of cancer research and clinical oncology (01.11.2015)
Published in Journal of cancer research and clinical oncology (01.11.2015)
Get full text
Journal Article
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
Giles, Francis J., Yin, Ophelia Q. P., Sallas, William M., le Coutre, Philipp D., Woodman, Richard C., Ottmann, Oliver G., Baccarani, Michele, Kantarjian, Hagop M.
Published in European journal of clinical pharmacology (01.04.2013)
Published in European journal of clinical pharmacology (01.04.2013)
Get full text
Journal Article
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
Larson, Richard A., Yin, Ophelia Q. P., Hochhaus, Andreas, Saglio, Giuseppe, Clark, Richard E., Nakamae, Hirohisa, Gallagher, Neil J., Demirhan, Eren, Hughes, Timothy P., Kantarjian, Hagop M., le Coutre, Philipp D.
Published in European journal of clinical pharmacology (01.05.2012)
Published in European journal of clinical pharmacology (01.05.2012)
Get full text
Journal Article
Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response
O’Dwyer, Michael E, Swords, Ronan, Nagler, Arnon, McMullin, Mary Frances, le Coutre, Philipp D, Langabeer, Stephen E, Alvarez-Iglesias, Alberto, Fan, Hongxin, Woodman, Richard C, Giles, Francis J, Conneally, Eibhlin
Published in Leukemia research (01.03.2014)
Published in Leukemia research (01.03.2014)
Get full text
Journal Article
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
Cortes, Jorge E., Hochhaus, Andreas, le Coutre, Philipp D., Rosti, Gianantonio, Pinilla-Ibarz, Javier, Jabbour, Elias, Gillis, Kathryn, Woodman, Richard C., Blakesley, Rick E., Giles, Francis J., Kantarjian, Hagop M., Baccarani, Michele
Published in Blood (26.05.2011)
Published in Blood (26.05.2011)
Get full text
Journal Article
Ponatinib in Heavily Pretreated Leukemia: 3-Year PACE Trial Results
Cortes, Jorge E, Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D, Paquette, Ronald, Chuah, Charles, Nicolini, Franck E, Apperley, Jane F, Khoury, H Jean, Talpaz, Moshe, DeAngelo, Daniel J, Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C, Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Tim, Haluska, Frank G, Guilhot, François, Deininger, Michael W, Hochhaus, Andreas, Hughes, Timothy P, Shah, Neil P, Kantarjian, Hagop M
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2015)
Get full text
Journal Article
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study
Hochhaus, Andreas, le Coutre, Philipp D., Kantarjian, Hagop M., Baccarani, Michele, Erben, Philipp, Reiter, Andreas, McCulloch, Tracey, Fan, Xiaolin, Novick, Steven, Giles, Francis J.
Published in Journal of cancer research and clinical oncology (01.12.2013)
Published in Journal of cancer research and clinical oncology (01.12.2013)
Get full text
Journal Article
PACE: A Pivotal Phase 2 Trial of Ponatinib in Patients With CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or With the T315I Mutation
Cortes, Jorge E, Kim, Dong-Wook, Pinilla, Javier, Paquette, Ronald, le Coutre, Philipp D, Chuah, Charles, Nicolini, Franck E, Apperley, Jane F, Jean Khoury, H, Talpaz, Moshe, DiPersio, John F, DeAngelo, Daniel J, Rea, Delphine, Abruzzese, Elisabetta, Mueller, Martin C, Baccarani, Michele, Gambacorti-Passerini, Carlo, Turner, Christopher D, Haluska, Frank, Kantarjian, Hagop M
Published in Clinical lymphoma, myeloma and leukemia (01.09.2013)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2013)
Get full text
Journal Article
Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION
Breccia, Massimo, Mauro, Michael J., Jabbour, Elias, Saglio, Giuseppe, Jiménez-Velasco, Antonio, le Coutre, Philipp D, DeGutis, Irene, Khan, Wasiulla, Sy, Oumar, Swanink, Rene, Cortes, Jorge E.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)
Gambacorti-Passerini, Carlo, Alvarez-Larrán, Alberto, Assouline, Sarit E, Pregno, Patrizia, le Coutre, Philipp D, Saussele, Susanne, Antolini, Laura, Druker, Brian J.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
Cortes, Jorge E., le Coutre, Philipp D, Gambacorti-Passerini, Carlo, Hjorth-Hansen, Henrik, Raanani, Pia, Garcia-Gutiérrez, Valentín, Kota, Vamsi, Purcell, Simon, Viqueira, Andrea, Leip, Eric, Brümmendorf, Tim H
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
Mauro, Michael J., Minami, Yosuke, Rea, Delphine, Hochhaus, Andreas, Lomaia, Elza, Voloshin, Sergey, Turkina, Anna G., Kim, Dong-Wook, Apperley, Jane F, Cortes, Jorge E., Abdo, Andre N.R., Fogliatto, Laura, Kim, Dennis Dong Hwan, le Coutre, Philipp D, Saussele, Susanne, Annunziata, Mario, Hughes, Timothy P., Chaudhri, Naeem A., Chee, Lynette C.Y., Garcia Gutierrez, Valentín, Sasaki, Koji, Kapoor, Shruti, Allepuz, Alex, Quenet, Sarah, Bédoucha, Véronique, Boquimpani, Carla
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
Hochhaus, Andreas, Boquimpani, Carla, Rea, Delphine, Minami, Yosuke, Lomaia, Elza, Voloshin, Sergey, Turkina, Anna G., Kim, Dong-Wook, Apperley, Jane, Cortes, Jorge E., Abdo, Andre, Fogliatto, Laura Maria, Kim, Dennis Dong Hwan, le Coutre, Philipp D, Saussele, Susanne, Annunziata, Mario, Hughes, Timothy P., Chaudhri, Naeem A., Chee, Lynette C.Y., García Gutiérrez, Valentín, Sasaki, Koji, Aimone, Paola, Allepuz, Alex, Quenet, Sarah, Bédoucha, Véronique, Mauro, Michael J.
Published in Blood (19.11.2020)
Published in Blood (19.11.2020)
Get full text
Journal Article